These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 17545614

  • 1. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death.
    Sui M, Huang Y, Park BH, Davidson NE, Fan W.
    Cancer Res; 2007 Jun 01; 67(11):5337-44. PubMed ID: 17545614
    [Abstract] [Full Text] [Related]

  • 2. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M, Jiang D, Hinsch C, Fan W.
    Breast Cancer Res Treat; 2010 Jun 01; 121(2):335-45. PubMed ID: 19626437
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
    Jiang D, Huang Y, Han N, Xu M, Xu L, Zhou L, Wang S, Fan W.
    Cancer Lett; 2014 May 01; 346(2):292-9. PubMed ID: 24462822
    [Abstract] [Full Text] [Related]

  • 5. Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer.
    Tokuda E, Seino Y, Arakawa A, Saito M, Kasumi F, Hayashi S, Yamaguchi Y.
    Breast Cancer Res Treat; 2012 Jun 01; 133(2):427-36. PubMed ID: 21909982
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.
    Shi J, Chen Y, Chen W, Tang C, Zhang H, Chen Y, Yang X, Xu Z, Wei J, Chen J.
    J Cell Mol Med; 2018 Nov 01; 22(11):5220-5230. PubMed ID: 30179299
    [Abstract] [Full Text] [Related]

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
    Anticancer Res; 2006 Nov 01; 26(3A):1773-84. PubMed ID: 16827106
    [Abstract] [Full Text] [Related]

  • 10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.
    Breast Cancer Res Treat; 2010 Jul 01; 122(2):395-407. PubMed ID: 19847644
    [Abstract] [Full Text] [Related]

  • 11. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
    Jiang Z, Guo J, Shen J, Jin M, Xie S, Wang L.
    J Exp Clin Cancer Res; 2012 May 03; 31(1):42. PubMed ID: 22553917
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of synuclein-gamma expression increases the sensitivity of breast cancer cells to paclitaxel treatment.
    Zhou Y, Inaba S, Liu J.
    Int J Oncol; 2006 Jul 03; 29(1):289-95. PubMed ID: 16773211
    [Abstract] [Full Text] [Related]

  • 13. Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest.
    Dziadyk JM, Sui M, Zhu X, Fan W.
    Anticancer Res; 2004 Jul 03; 24(1):27-36. PubMed ID: 15015572
    [Abstract] [Full Text] [Related]

  • 14. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D.
    Clin Cancer Res; 2007 Dec 01; 13(23):7029-36. PubMed ID: 18056179
    [Abstract] [Full Text] [Related]

  • 15. Microtubule-binding protein CLIP-170 is a mediator of paclitaxel sensitivity.
    Sun X, Li D, Yang Y, Ren Y, Li J, Wang Z, Dong B, Liu M, Zhou J.
    J Pathol; 2012 Mar 01; 226(4):666-73. PubMed ID: 21989536
    [Abstract] [Full Text] [Related]

  • 16. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 17. Potentiation of paclitaxel effect by resveratrol in human breast cancer cells by counteracting the 17β-estradiol/estrogen receptor α/neuroglobin pathway.
    Cipolletti M, Montalesi E, Nuzzo MT, Fiocchetti M, Ascenzi P, Marino M.
    J Cell Physiol; 2019 Apr 01; 234(4):3147-3157. PubMed ID: 30421506
    [Abstract] [Full Text] [Related]

  • 18. The vitamin A family can significantly decrease the expression of ERbeta of ERs positive breast cancer cells in the presence or absence of ER ligands and paclitaxel.
    Czeczuga-Semeniuk E, Jarzabek K, Lemancewicz D, Wołczyński S.
    Gynecol Endocrinol; 2009 May 01; 25(5):287-93. PubMed ID: 19340624
    [Abstract] [Full Text] [Related]

  • 19. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
    Dong XL, Xu PF, Miao C, Fu ZY, Li QP, Tang PY, Wang T.
    Biomed Pharmacother; 2012 Feb 01; 66(1):70-5. PubMed ID: 22264882
    [Abstract] [Full Text] [Related]

  • 20. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.
    Oncogene; 2002 Jun 06; 21(25):4000-8. PubMed ID: 12037682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.